Combination antiviral therapy for influenza: predictions from modeling of human infections.
about
Viral kinetic modeling: state of the artQuantification of viral infection dynamics in animal experimentsInfluenza treatment and prophylaxis with neuraminidase inhibitors: a reviewIntra- and inter-pandemic variations of antiviral, antibiotics and decongestants in wastewater treatment plants and receiving riversThe potential for respiratory droplet-transmissible A/H5N1 influenza virus to evolve in a mammalian host.The use of antiviral drugs for influenza: Guidance for practitioners 2012/2013Quantifying the fitness advantage of polymerase substitutions in Influenza A/H7N9 viruses during adaptation to humans.Towards multiscale modeling of influenza infectionCombination therapy with amantadine, oseltamivir and ribavirin for influenza A infection: safety and pharmacokineticsEuropean guidelines for prevention and management of influenza in hematopoietic stem cell transplantation and leukemia patients: summary of ECIL-4 (2011), on behalf of ECIL, a joint venture of EBMT, EORTC, ICHS, and ELN.How sticky should a virus be? The impact of virus binding and release on transmission fitness using influenza as an example.Exploring virus release as a bottleneck for the spread of influenza A virus infection in vitro and the implications for antiviral therapy with neuraminidase inhibitors.Modelling the emergence of influenza drug resistance: The roles of surface proteins, the immune response and antiviral mechanisms.Treatment of Immunocompromised, Critically Ill Patients with Influenza A H1N1 Infection with a Combination of Oseltamivir, Amantadine, and Zanamivir.Expected Effect of Deleterious Mutations on Within-Host Adaptation of Pathogens.Antibody Immunodominance: The Key to Understanding Influenza Virus Antigenic Drift.Host-pathogen kinetics during influenza infection and coinfection: insights from predictive modelingInvestigating Different Mechanisms of Action in Combination Therapy for Influenza
P2860
Q26824655-59A055F9-5D7D-4F59-9A62-46CE30259A51Q26824804-4F233FE4-8BAB-4724-831D-BF234209A234Q26860032-E0AD6987-CF46-48FF-BD9E-A62D98057332Q28543255-9504D26B-16CE-4A39-8381-6762E90B43D8Q30418377-B877078F-8987-4885-8290-131A5E3E869BQ34389114-3799F405-6E20-46BA-B25A-1A8647B0330DQ35006157-9D379C66-DE4B-40CF-BFF5-53913BE082ADQ37136609-9544CDFD-B2B2-4589-B45A-FC8E5E0998E3Q37549382-A3FE3CE1-B3D2-4BF2-9EE9-97DAFD32C941Q38077827-31C35B51-244F-4FDF-A171-CBA86B4DE843Q39271411-D0032B14-384A-491E-875F-D75C5A12A980Q40072156-0FAA20AC-3EC8-4832-8258-15C9EA1B1DA5Q40138039-624B0FFC-0F63-4DA3-8099-15918E6FCF6CQ41011707-81CD3CEB-F4B6-4FFB-B429-BC7F17F89662Q41140967-E2D19ADA-8CA0-46B1-B767-74AD495B6960Q47550457-83AF21DC-B615-48CA-AC66-DD81A32A473AQ57232542-6FD17605-AC46-4C7D-8A0C-8155CDB0EA1AQ58573517-980E17B8-2207-4513-A7C5-EE2A0C9208AA
P2860
Combination antiviral therapy for influenza: predictions from modeling of human infections.
description
2012 nî lūn-bûn
@nan
2012 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի մարտին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Combination antiviral therapy ...... modeling of human infections.
@ast
Combination antiviral therapy ...... modeling of human infections.
@en
type
label
Combination antiviral therapy ...... modeling of human infections.
@ast
Combination antiviral therapy ...... modeling of human infections.
@en
prefLabel
Combination antiviral therapy ...... modeling of human infections.
@ast
Combination antiviral therapy ...... modeling of human infections.
@en
P2860
P356
P1476
Combination antiviral therapy ...... modeling of human infections.
@en
P2093
Libin Rong
P2860
P304
P356
10.1093/INFDIS/JIS265
P407
P577
2012-03-23T00:00:00Z